| IMMUNITYBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US45256X1037 / A2QQ2E |
| 26CA (Frankfurt) / IBRX (NASDAQ) |
| FRA:26CA, ETR:26CA, 26CA:GR, NASDAQ:IBRX |
| - |
| https://immunitybio.com/ |
|
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage ..
>Volltext.. |
| 4948.99 Mio. EUR |
| 5464.76 Mio. EUR |
| 69.77 Mio. EUR |
| -207.02 Mio. EUR |
| -294.64 Mio. EUR |
| -0.34 EUR |
| 727.89 Mio. EUR |
| 50.91 Mio. EUR |
| -270.2 Mio. EUR |
| 4.51 |
| 968.35% |
| 43.72% |
| - |
| - |
| - |
| IMMUNITYBIO |
| 18.02.26 |
|